V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160014577 | 160007169 | 1.6 | 71 | Palliative (P) | 2019-02-16 | 2019-02-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101013198 |
| 160014582 | 160007170 | 1.61 | 116.8 | Palliative (P) | null | 2018-02-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100440572 |
| 160014583 | 160007171 | 1.73 | 95.8 | Palliative (P) | 2018-09-30 | 2018-10-02 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100308658 |
| 160014586 | 160007172 | 1.73 | 82.9 | Not known (9) | 2017-02-22 | 2017-03-06 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100657445 |
| 160014587 | 160007173 | 0 | 7.7 | Palliative (P) | 2016-11-28 | 2016-12-08 | Cisplatin + Paclitaxel | N | N | DOXORUBICIN + IFOSFAMIDE | 100594103 |
| 160014594 | 160007174 | 1.78 | 72.2 | Palliative (P) | 2018-12-04 | 2018-12-05 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100589860 |
| 160014596 | 160007175 | 1.68 | 99.7 | Neo-adjuvant (N) | 2017-01-01 | 2017-01-11 | Bevacizumab 7.5mg/kg | N | null | CYCLOPHOSPHAMIDE | 100696749 |
| 160014597 | 160007176 | 1.5 | 64.5 | Curative (C) | 2016-06-25 | 2016-07-02 | Rituximab | 02 | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 101418899 |
| 160014598 | 160007177 | 1.77 | 115.25 | Palliative (P) | 2019-02-15 | 2019-06-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100224523 |
| 160014599 | 160007178 | 1.92 | 100.8 | Curative (C) | 2017-03-24 | 2017-04-13 | DOXORUBICIN | 02 | N | CYCLOPHOSPHAMIDE | 101830852 |
| 160014600 | 160007179 | 1.72 | 90 | Neo-adjuvant (N) | 2018-12-27 | 2018-12-29 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100223032 |
| 160014601 | 160007180 | null | null | Neo-adjuvant (N) | 2016-08-06 | 2016-08-13 | Doxorubicin 75mg/m2 | N | null | DOXORUBICIN | 100714642 |
| 160014604 | 160007181 | 1.67 | 112 | Palliative (P) | 2018-07-28 | 2018-07-29 | FEC 60 or 75 | N | N | SUNITINIB | 100946772 |
| 160014605 | 160007182 | 1.7 | 60 | null | 2019-04-17 | 2019-05-06 | Trial Unspecified | N | null | DOXORUBICIN + OLARATUMAB | 101584725 |
| 160014606 | 160007183 | 1.82 | 72.3 | Palliative (P) | 2016-08-22 | 2016-09-05 | IVA | null | null | EW EUROEWING 2012 ARM B VDC | 101108328 |
| 160014607 | 160007184 | 1.51 | 11 | 03 | 2016-09-15 | 2016-10-06 | Liposomal Doxorubicin (Caelyx) | 02 | N | CISPLATIN + PEMETREXED | 101413585 |
| 160014608 | 160007185 | 1.72 | 112 | Neo-adjuvant (N) | 2019-04-09 | 2019-04-11 | DOXORUBICIN | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100634629 |
| 160014609 | 160007186 | 1.85 | 77.3 | Palliative (P) | null | 2013-09-29 | IVADo | 02 | N | CARBOPLATIN | 101479521 |
| 160014610 | 160007187 | 1.69 | 61.1 | Palliative (P) | 2019-09-21 | 2019-09-21 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101118873 |
| 160014612 | 160007189 | 1.7 | 82.8 | Palliative (P) | 2017-02-16 | 2017-03-06 | Doxorubicin + Ifosfamide | 01 | N | FLUOROURACIL + OXALIPLATIN | 101656883 |
| 160014617 | 160007190 | 0 | 19.5 | Palliative (P) | 2016-11-17 | 2016-11-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100431435 |
| 160014619 | 160007191 | null | 81 | Palliative (P) | 2017-02-27 | 2017-03-25 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101076022 |
| 160014620 | 160007192 | 1.7 | 60 | Palliative (P) | 2017-07-19 | 2017-08-06 | STS Rhabdomyosarco RMS 2005 IVADoVV | N | N | EURO-EWING | 100697434 |
| 160014622 | 160007193 | 1.81 | 69.5 | null | 2018-02-15 | 2018-03-01 | BEP 5 Day | 02 | N | LIPOSOMAL DOXORUBICIN | 100227284 |
| 160014623 | 160007194 | 1.76 | 56.3 | Palliative (P) | null | 2016-09-22 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101561652 |
| 160014624 | 160007195 | 1.67 | 79.8 | Curative (C) | 2016-06-15 | 2016-06-23 | Cisplatin + Pemetrexed | 02 | N | NB HRNBL-1 COJEC IND COURSE A | 100917785 |
| 160014625 | 160007196 | null | null | null | 2020-10-25 | 2020-11-01 | Doxorubicin + Olaratumab | 02 | null | SUNITINIB | 100440508 |
| 160014627 | 160007197 | 1.55 | 86.5 | 03 | 2018-03-28 | 2018-04-04 | Liposomal Doxorubicin (Caelyx) | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100302354 |
| 160014628 | 160007198 | 1.6 | 58.1 | Neo-adjuvant (N) | null | 2016-08-06 | Doxorubicin + Olaratumab | 02 | N | TRIAL UNSPECIFIED | 100942502 |
| 160014630 | 160007199 | null | null | null | 2018-09-10 | 2018-09-10 | CARBOPLATIN + PACLITAXEL | 01 | null | CARBOPLATIN + PACLITAXEL | 100485735 |
| 160014631 | 160007200 | 1.52 | 104.7 | Palliative (P) | 2017-06-03 | 2017-06-03 | OCTREOTIDE | 02 | N | LIPOSOMAL DOXORUBICIN | 101777291 |
| 160014632 | 160007201 | 1.65 | 61 | Palliative (P) | null | 2018-02-26 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101668835 |
| 160014633 | 160007202 | 1.6 | 82.5 | Curative (C) | 2017-12-07 | 2017-12-07 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100508107 |
| 160014634 | 160007203 | 1.68 | 85.1 | null | 2018-04-06 | 2018-04-13 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101617506 |
| 160014637 | 160007204 | 1.72 | 59.8 | Disease modification (D) | 2016-07-02 | 2016-07-05 | VAC | 02 | N | TRIAL UNSPECIFIED | 100867894 |
| 160014641 | 160007205 | 1.73 | 80.3 | null | 2018-04-20 | 2018-05-09 | Pemetrexed | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100147941 |
| 160014644 | 160007206 | 1.82 | 10.7 | Neo-adjuvant (N) | 2018-04-13 | 2018-04-15 | Cisplatin + Doxorubicin | N | N | GEMCARBO | 100692457 |
| 160014645 | 160007207 | 0 | 59.8 | Neo-adjuvant (N) | 2018-04-01 | 2018-04-08 | Trabectedin | 02 | N | TRIAL UNSPECIFIED | 101295050 |
| 160014646 | 160007208 | 1.31 | 52.8 | Palliative (P) | 2018-09-13 | 2018-09-13 | Carboplatin + Paclitaxel (3 weekly) | N | N | CARBOPLATIN + PACLITAXEL | 100734141 |
| 160014647 | 160007209 | 1.43 | 68.2 | Palliative (P) | 2017-08-04 | 2017-08-06 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100324751 |
| 160014649 | 160007210 | 1.79 | 86 | Palliative (P) | 2019-07-21 | 2019-08-06 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100634635 |
| 160014651 | 160007211 | 1.7 | 77 | Adjuvant (A) | 2017-03-23 | 2017-04-16 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | TRIAL | 101186435 |
| 160014653 | 160007212 | 1.6 | 67.8 | Neo-adjuvant (N) | 2016-06-16 | 2016-06-19 | Cisplatin + Doxorubicin | 02 | N | IVA | 101849232 |
| 160014655 | 160007213 | 1.66 | 58.7 | Curative (C) | null | null | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101341540 |
| 160014656 | 160007214 | 1.78 | 86.8 | Palliative (P) | 2016-11-14 | 2016-11-18 | Cisplatin + Pemetrexed | 02 | N | TRABECTEDIN | 101840358 |
| 160014657 | 160007215 | 1.86 | 92.8 | null | 2018-05-05 | 2018-05-08 | Hydroxycarbamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101066987 |
| 160014658 | 160007216 | 1.78 | 83.65 | Palliative (P) | 2018-08-10 | 2018-08-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101469754 |
| 160014660 | 160007217 | 1.69 | 87.4 | Palliative (P) | 2019-09-10 | 2019-10-03 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100048351 |
| 160014661 | 160007218 | 1.63 | 57.2 | Neo-adjuvant (N) | 2017-04-05 | 2017-04-13 | PACLITAXEL | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100456004 |
| 160014662 | 160007219 | 1.77 | 48.6 | Neo-adjuvant (N) | null | 2018-01-18 | Doxorubicin 75mg/m2 | 02 | N | GC INT GUIDE EXCRANIAL GERMCELL JEB | 100564755 |